PRME Prime Medicine, Inc.

Nasdaq primemedicine.com


$ 5.63 $ 0.00 (0 %)    

Monday, 20-Oct-2025 08:55:39 EDT
QQQ $ 607.72 $ 0.00 (0 %)
DIA $ 463.60 $ 0.00 (0 %)
SPY $ 667.53 $ 0.00 (0 %)
TLT $ 91.51 $ 0.00 (0 %)
GLD $ 397.60 $ 0.00 (0 %)
$ 5.45
$ 5.65
$ 5.56 x 134
$ 5.69 x 500
-- - --
$ 1.11 - $ 6.94
3,566,335
na
nm
$ 2.20
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-10

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 prime-medicine-q2-eps-041-misses-039-estimate-sales-1115m-beat-750000k-estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0....

 prime-medicine-announces-proposed-public-offering-of-common-stock-no-size-or-amount-disclosed

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time cura...

 citigroup-downgrades-prime-medicine-to-neutral-lowers-price-target-to-15

Citigroup analyst Samantha Semenkow downgrades Prime Medicine (NASDAQ:PRME) from Buy to Neutral and lowers the price target ...

 jmp-securities-maintains-market-outperform-on-prime-medicine-lowers-price-target-to-6

JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:PRME) with a Market Outperform and lowers the price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION